GENB
Generate BiomedicinesCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-20
Current thesis
The strongest support is operational: GENB exited Q1 with $516.6M of cash, says that funds operations into 1H28, and has multiple 2026 pipeline milestones, including mid-2026 GB-4362 dosing and 2H26 GB-5267 dosing, while GB-0895 remains in Phase 3 severe asthma [#SEC-8K-2026-05-07].
Posture
Mixed
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +3.2.
What can break
Clinical timelines for GB-4362 and GB-5267 could slip, removing the clearest 2026 execution hooks.
Momentum
51
Value
46
Sentiment
63
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $15.50 · Bull $24.50 · Bear $10.50
Data freshness
Prices
As of 2026-07-20
Fundamentals
As of 2026-07-20 • Vendor: Data Vendor v1
Scores
As of 2026-07-20 • Model: HYBRID_IC_RP
AI Memo
As of 2026-07-01 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-20
Investment thesis
As of 2026-07-20
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $25.40
Why
Momentum51 · Δ7d -4.8
Value46 · Δ7d +0.0
Sentiment63 · Δ7d +3.2
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Sentiment · See AI snapshot
Momentum
51
26% active weight
Current posture
7d trendSoftening
Δ7d
-4.8
Δ21d
-9.3
Value
46
39% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
+0.0
Sentiment
63
34% active weight
Current posture
7d trendImproving
Δ7d
+3.2
Δ21d
-
Why this grade
Composite grade C. Momentum 50.6 / Value 46.4 / Sentiment 63.5
Fundamentals (TTM)As of 2026-07-20
Fundamentals (TTM)
As of 2026-07-20
Market Cap
$1.74B
Beta
-
Shares Out
128.19M
P/E (TTM) · Derived
-6.9
P/S (TTM)
-
P/FCF (TTM)
-
Rev YoY
-18.1%
EPS YoY
-66.6%
Gross Margin
-
Op Margin
-
Net Debt
-$153.31M
Current Ratio
9.17
As of 2026-07-20 • Updated nightlySource: Internal modelMethodology